Abstract
Graves' orbitopathy or thyroid associated orbitopathy (TAO) is a disquieting condition both for the patient and the clinician. While the mainstay of treatment of the orbitopathy is corticosteroids, its action is non-specific. The arguments against its use also include multiple side effects and recurrence on stopping it. While some clinicians are complacent with the drug due to our long term experience with it, many are in search for specific so called 'targeted' treatment. The autoimmune process in TAO is rather complex where multiple cytokines act at more than one level making it challenging to control the inflammation. Hence, in order to discover better treatment strategies, having a sound understanding of the pathogenesis of the disease is essential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JPMA. The Journal of the Pakistan Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
